Oak Hill Bio

Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been deprioritized by big pharma. The company's lead program is rugonersen (OHB-724), an investigational oligonucleotide entering Phase 3 that has best-in-class potential as a treatment for Angelman syndrome, a devastating neurodevelopmental disorder with no approved disease-modifying therapies.